Vancomycin
FDA-approved product (solution, intravenous, oral), marketed as Vancomycin, Firvanq Kit, Tyzavan and 5 more.
- Registered studies
- 50+
- Lab records
- 118
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Bacterial disease
- Diarrhea
- Endocarditis
- Enterocolitis
- Eye infection
- Infection
- Infective endocarditis
- Respiratory tract infectious disorder
- Sepsis
- Skin disease
- Skin infection
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antibiotics; Glycopeptide antibacterials
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J01XA01; WHO ATC A07AA09; WHO ATC S01AA28
Repurposing investigation
Vancomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- E. coli78.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- K. pneumoniae80.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
- M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
- MRSA: measured active in 103 of 103 lab records
- E. coli: measured active in 8 of 9 lab records
- K. pneumoniae: measured active in 2 of 3 lab records
- M. tuberculosis: measured active in 0 of 3 lab records
Show the 118 laboratory records, with sources
Loading records…
“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Vancomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization
NCT02814318 · start 2016-06
Registered record
- Registry ID
- NCT02814318
- Conditions
- Group B Streptococcal Infection
- Interventions
- Vaginal and rectovaginal swab cultures
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Terminated
- Start
- 2016-06
- Completion
- 2019-10
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGroup B Streptococcal InfectionInterventionVaginal and rectovaginal swab culturesPhaseNot recordedRegistry statusTerminatedCohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci
NCT02623413 · start 2016-01
Registered record
- Registry ID
- NCT02623413
- Conditions
- Vancomycin (Glycopeptide) Resistant Enterococcus (VRE); Cancer
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2016-01
- Completion
- 2017-03
- Enrolment
- 950
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionVancomycin (Glycopeptide) Resistant Enterococcus (VRE); CancerInterventionNot recordedPhaseNot recordedRegistry statusUnknownTwo Versus Four Weeks of Antibiotic Treatment in Native Joint Arthritis
NCT03615781 · start 2015-06-01
Registered record
- Registry ID
- NCT03615781
- Conditions
- Arthritis, Septic
- Interventions
- Two week's arm - surgery; Four week's arm - surgery; Two week's arm - drugs; Four week's arm - drugs
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2015-06-01
- Completion
- 2018-05-18
- Enrolment
- 85
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionArthritis, SepticInterventionTwo week's arm - surgery; Four week's arm - surgery; Two week's arm - drugs; Four week's arm - drugsPhaseNot applicableRegistry statusCompletedFMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment
NCT02570477 · start 2015-01
Registered record
- Registry ID
- NCT02570477
- Conditions
- Clostridium Difficile Infection
- Interventions
- Fecal Microbiota Transplantation; Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2015-01
- Completion
- 2024-12
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionClostridium Difficile InfectionInterventionFecal Microbiota Transplantation; VancomycinPhaseNot applicableRegistry statusUnknownIntrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis
NCT02143154 · start 2014-10
Registered record
- Registry ID
- NCT02143154
- Conditions
- GBS Positive; Women in Labor Given Vancomycin for Prophylaxis
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2014-10
- Completion
- 2018-10-03
- Enrolment
- 77
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionGBS Positive; Women in Labor Given Vancomycin for ProphylaxisInterventionNot recordedPhaseNot recordedRegistry statusCompletedTopical Vancomycin for Neurosurgery Wound Prophylaxis
NCT02284126 · start 2014-10
Registered record
- Registry ID
- NCT02284126
- Conditions
- Infection; Surgery; Nervous System Diseases
- Interventions
- Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-10
- Completion
- 2020-11
- Enrolment
- 1,103
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfection; Surgery; Nervous System DiseasesInterventionVancomycinPhasePhase 3Registry statusCompletedEfficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
NCT01987895 · start 2014-03-27
Registered record
- Registry ID
- NCT01987895
- Conditions
- Clostridium Difficile Infection
- Interventions
- Cadazolid; Vancomycin; Cadazolid-matching placebo; Vancomycin-matching placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-03-27
- Completion
- 2017-03-24
- Enrolment
- 632
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionClostridium Difficile InfectionInterventionCadazolid; Vancomycin; Cadazolid-matching placebo; Vancomycin-matching placeboPhasePhase 3Registry statusCompletedDose Escalation Trial of Intrasite Vancomycin Pharmacokinetics
NCT01764750 · start 2013-01
Registered record
- Registry ID
- NCT01764750
- Conditions
- Surgical Site Infection
- Interventions
- Intrasite Vancomycin; IV Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2013-01
- Completion
- 2013-12
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSurgical Site InfectionInterventionIntrasite Vancomycin; IV VancomycinPhasePhase 1Registry statusTerminatedSafety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)
NCT01669980 · start 2012-10
Registered record
- Registry ID
- NCT01669980
- Conditions
- Infections; Pneumonia
- Interventions
- Ceftaroline fosamil; IV Ceftriaxone and Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2012-10
- Completion
- 2014-08
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInfections; PneumoniaInterventionCeftaroline fosamil; IV Ceftriaxone and VancomycinPhasePhase 4Registry statusCompletedOptimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices
NCT01661361 · start 2012-09
Registered record
- Registry ID
- NCT01661361
- Conditions
- Catheter-related Infection
- Interventions
- blood levels
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2012-09
- Completion
- 2012-12
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCatheter-related InfectionInterventionblood levelsPhaseNot recordedRegistry statusUnknownDaptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
NCT01515020 · start 2012-05
Registered record
- Registry ID
- NCT01515020
- Conditions
- Nosocomial Infection; Healthcare-associated Infection
- Interventions
- vancomycin monotherapy; daptomycin monotherapy
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2012-05
- Completion
- 2014-07
- Enrolment
- 10
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNosocomial Infection; Healthcare-associated InfectionInterventionvancomycin monotherapy; daptomycin monotherapyPhasePhase 3Registry statusTerminatedEffects of MRSA Bactericidal Gel To Promote Healing and Eliminate MRSA in cSSTI Vancogel(TM)
NCT00945152 · start 2011-07-15
Registered record
- Registry ID
- NCT00945152
- Conditions
- Bacterial Infections; Wounds
- Interventions
- Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R); Placebo, complex gel formulation without Vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Unknown
- Start
- 2011-07-15
- Completion
- 2024-12-15
- Enrolment
- 100
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial Infections; WoundsInterventionVancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R); Placebo, complex gel formulation without VancomycinPhasePhase 2Registry statusUnknownA Study of Ceftobiprole in Patients With Fever and Neutropenia.
NCT00529282 · start 2007-10
Registered record
- Registry ID
- NCT00529282
- Conditions
- Fever; Neutropenia; Gram-positive Bacterial Infections; Pseudomonas Infection
- Interventions
- Ceftobiprole Medocaril; Cefepime with or without vancomycin
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Terminated
- Start
- 2007-10
- Completion
- 2008-01
- Enrolment
- 2
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionFever; Neutropenia; Gram-positive Bacterial Infections; Pseudomonas InfectionInterventionCeftobiprole Medocaril; Cefepime with or without vancomycinPhasePhase 3Registry statusTerminatedVancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis
NCT00967941 · start 2007-08
Registered record
- Registry ID
- NCT00967941
- Conditions
- MRSA Infections
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2007-08
- Completion
- 2010-08
- Enrolment
- 169
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMRSA InfectionsInterventionNot recordedPhaseNot recordedRegistry statusCompletedComparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
NCT00424190 · start 2007-02
Registered record
- Registry ID
- NCT00424190
- Conditions
- Bacterial Infections
- Interventions
- IV Vancomycin plus IV Aztreonam; Ceftaroline
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-02
- Completion
- 2007-11
- Enrolment
- 698
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBacterial InfectionsInterventionIV Vancomycin plus IV Aztreonam; CeftarolinePhasePhase 3Registry statusCompleted